

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED
SECRETARY OF THE
PUBLIC RECORD

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Organization	sanofi-aventis		
2. Address <input checked="" type="checkbox"/> Check if different than previously reported			
Address1	801 Pennsylvania Avenue, NW	Suite	725
City	Washington	State	DC
		Zip Code	20004
			Country USA
3. Principal place of business (if different than line 2)			
City	Bridgewater	State	NJ
		Zip Code	08807-2854
			Country USA
4a. Contact Name		b. Telephone number	c. E-mail
Prefix	Full Name		
Mr.	Jonathan Spear	202-628-0500	jonathan.spear@sanofi-aventis.com
7. Client Name <input checked="" type="checkbox"/> Self			5. Senate ID #
sanofi-aventis			56838-12
			6. House ID #
			35186000

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u> </u></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u> </u> 2,380,000</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

0000082832

Form CD



Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the r engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

HR 2744 House Agriculture Appropriations, provisions and issues related to the importation of prescription drugs; S. 1932 Deficit Reduction Omnibus Reconciliation Act of 2005, provisions related to Medicaid; HR 4241 Deficit Reduction Act of 2005, provisions related to Medicaid; and House and Senate Budget Bills, provisions related to the federal government not interfering with negotiations between private insurance plans and pharmaceutical manufacturers on prescription drugs

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Ann	Taylor		N/A
Judy	Cook		N/A
Richard	Hodge		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

3000082833

Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the r engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code.** information as requested. Attach additional page(s) as needed.

15. General issue area code TOR - Torts (one per page)

16. Specific lobbying issues

HR 5 Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2005

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Ann	Taylor		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000082834

Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the r engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Medicare Part D Implementation; Coding for Medicare Part B Product

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health and Human Services (DHHS)
US House of Representatives
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Ann	Taylor		N/A
Eddie	Evans		N/A
Saira	Sultan		N/A
Jonathan	Spear		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000082835

Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

Discussions related to Congressional intent of the Veterans Healthcare of 1994 and the TRICARE program regarding the provisions related to reimbursement for prescription drugs

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives
US Senate
Department of Veterans Affairs
Department of Defense

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Richard	Hodge		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000082836

Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

HR 2862, FY 2006 Commerce, Justice and Science Appropriations, provisions or amendments related to importation; HR 3196 Fair Access to Clinical Trials Act; and S.470 Fair Access to Clinical Trials Act

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives
 US Senate
 Department of Health and Human Services (DHHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Ann	Taylor		N/A
Judy	Cook		N/A
Richard	Hodge		N/A
Eddie	Evans		N/A
Saira	Sultan		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000082837

Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide the information as requested. Attach additional page(s) as needed.

15. General issue area code MED - Medical/Disease Research/Clinical Labs (one per page)

16. Specific lobbying issues

The Animal Enterprise Terrorism Act

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives
US Senate
Department of Health and Human Services (DHHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Saira	Sultan		N/A
Judy	Cook		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000082838

Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

HR 2795, Patent Reform Act of 2005, and other draft patent reform proposals

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Judy	Cook		N/A
Eddie	Evans		N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000082839



Registrant Name sanofi-aventis Client Name sanofi-aventis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code _____ (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000082840

Add a page for a differer

Registrant Name sanofi-aventis Client Name sanofi-aventis

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address

City

State

Zip Code

Country

21. Client new principal place of business (if different than line 20)

City

State

Zip Code

Country

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

First Name

Last Name

Suffix

First Name

Last Name

Suffix

1

3

2

4

ISSUE UPDATE

Find the code to select below.

24. General lobbying issues that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State Country
	Address	City
	C/S/Z	State

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

1

2

3

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Street Address	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Owner percent client
	City	State/Province Country	City		
			State Country		

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

1

3

5

2

4

6

Add a page for more updates

Printed Name and Title Jonathan B. Spear, Associate Vice President, Federal Government Relations

1000082841

